Where precision antibacterials belong

Co-administer a narrow phage cocktail that selectively knocks back the pathobiont an antibiotic course is meant to hit, so the antibiotic dose (and its collateral destruction of commensals) can be reduced — a “microbiome airbag.”

Basis · Antibiotic-driven dysbiosis itself raises risk of C. difficile, NEC, and MDRO bloom. Phage’s strain specificity is the only tool that can subtract one species while sparing the rest.

After a fecal transplant or dietary intervention shifts a patient toward a healthy microbiome signature, deploy phages to suppress re-bloom of the displaced pathobiont and “lock in” the new equilibrium.

Basis · Donor phages already engraft and reshape recipient viromes after FMT; relapse is usually re-expansion of the original strain. Phage is the natural maintenance layer.

↳ A direct instrument for Microbiome Medicine’s Microbial Shift & Realignment Process (MSRP).

Catheters, prosthetic joints, contact lenses, sutures, and heart valves coated with phages that release on contact with their target biofilm — turning the most infection-prone hardware into its own antibacterial.

Basis · Device biofilms are the dominant failure mode of implants and are ~1,000× antibiotic-tolerant. Phage-loaded hydrogels and coatings show sustained release and biofilm clearance in vitro.

Sell phages chosen specifically because escaping them forces the bacterium to discard its antibiotic-resistance or virulence machinery — pairing the phage with an “obsolete” antibiotic to bring it back to life.

Basis · Yale’s OMKO1 binds an efflux-pump pore in P. aeruginosa; phage-resistant escape mutants lose drug resistance. “Phage steering” turns resistance into a fork the bacterium cannot win.

CRISPR-armed phages that deliver payloads to destroy antibiotic-resistance plasmids or virulence genes across a bacterial population, restoring drug susceptibility instead of selecting for resistant survivors.

Basis · Phage-delivered CRISPR-Cas can sequence-specifically cleave resistance genes; SNIPR and Eligo build on exactly this “edit, don’t just kill” logic.

A single engineered phage that both reports the presence of its exact target strain (a diagnostic signal) and lyses it — collapsing the days-long strain-matching bottleneck into one point-of-care test-and-treat.

Basis · Reporter phages (luciferase/fluorescence) already identify specific pathogens within hours; fusing detection with therapy is an unbuilt but tractable combination.

Replace broad intrapartum antibiotics with a targeted vaginal/gut phage cocktail that clears Group B Streptococcus or MDR Klebsiella from the mother before birth — protecting the newborn without erasing the microbiome it is about to inherit.

Basis · Intrapartum antibiotics perturb the founding neonatal microbiome (linked to later asthma, obesity, dysbiosis). Phage offers source control without that cost.

Sequence a newborn’s pioneer gut colonizers and pre-stage matched lytic phages as a personal biodefense reserve — so if a colonizer later turns invasive, the precision counter-agent already exists.

Basis · The neonatal gut is near-sterile at birth and assembles from a handful of pioneer strains; banking phages against them is a finite, achievable library.

Before stem-cell or organ transplant, strip only the specific gut MDRO that threatens the immunosuppressed patient, rather than carpet-bombing the whole gut with prophylactic antibiotics.

Basis · Gut-derived bloodstream infection is a leading cause of transplant mortality; SNIPR001’s gut E. coli decolonization is the first clinical proof this route works.

A cocktail aimed at urease-producing bacteria to simultaneously prevent infection (struvite) kidney stones, catheter encrustation, and ammonia-driven hepatic encephalopathy — one mechanism, three diseases.

Basis · Proteus and other urease+ organisms drive all three; selectively removing them lowers local ammonia and crystal nucleation without systemic antibiotics.

A stockpiled, inhalable phage cocktail against the staph and strep that cause lethal secondary pneumonia during respiratory pandemics — a non-antibiotic countermeasure that resistance can’t pre-empt.

Basis · Most influenza-pandemic deaths historically came from secondary bacterial pneumonia; phage cocktails can be re-matched faster than new antibiotics can be developed.

Target taxa whose virulence or toxicity is driven by trace-metal acquisition — or that mobilize toxic heavy metals in the gut — as a precision lever on the metal–microbe–disease axis.

Basis · Pathogen virulence is tightly coupled to metal scavenging (nutritional immunity); removing a metallophilic strain may disrupt disease without disturbing the community.

↳ Connects directly to Karen Pendergrass’s Journal of Food Metallomics and microbial-metallomics research.

A phage “pre-treatment” that depletes the specific intratumoral or gut strains known to blunt checkpoint-inhibitor response — sold as a companion to immuno-oncology, not a standalone antibiotic.

Basis · Fusobacterium and particular gut taxa modulate chemo and immunotherapy outcomes; phage is the only way to remove them selectively from a tumor.

Target the bacterial strains (e.g., Fusobacterium) newly implicated in endometriosis lesions and chronic pelvic inflammation as a precision, non-hormonal intervention.

Basis · Recent work links Fusobacterium infection to endometriosis pathogenesis in animal models and patient tissue; an anti-Fusobacterium phage is an obvious untested probe.

↳ Extends Karen Pendergrass’s endometriosis-microbiome triangulation work.

Distributed, GMP-in-a-box manufacturing that isolates and assembles a patient-matched cocktail from a clinical sample within days — the commercial moonshot that makes truly personalized phage scalable.

Basis · Personalized phage works best clinically but breaks the fixed-formulation drug model; microfluidic isolation + rapid host-range matching is the bottleneck a “phage pharmacy” dissolves.

Probe the strains implicated in Parkinson’s and Alzheimer’s — P. gingivalis, specific Desulfovibrio and gut clostridia — with strain-specific phages to test causal, microbiome-signature hypotheses in humans.

Basis · Disease-associated strains are now identified (e.g., P. gingivalis/gingipains in AD brains); phage is the cleanest tool to test whether removing one strain changes the phenotype.

↳ A testbed for Microbiome Medicine’s signature-validation framework.

Phage treatment of dialysis lines, endoscope channels, dental-unit waterlines, and hospital plumbing — the environmental biofilm reservoirs that seed device and surgical infections.

Basis · Pseudomonas and NTM biofilms in water systems are documented outbreak sources; phage biocontrol is already proven on food-contact surfaces.

A food-grade phage step that clears Cronobacter sakazakii from reconstituted formula — directly addressing a pathogen with up to ~80% neonatal mortality and recurring recall crises.

Basis · Multiple lytic phages clear C. sakazakii from reconstituted formula in the lab; this is a near-ready application of the established food-biocontrol model to a neonatal pathogen.

Skip the bacteria: a standardized, screened phage/virome preparation that delivers FMT’s benefit with none of the live-bacteria transmission risk — a manufacturable product, not a stool donation.

Basis · Sterile fecal-filtrate transfer cured recurrent C. difficile in 5/5 patients (phages retained, bacteria removed) and prevented NEC in piglets — the active fraction is increasingly the virome.